Tactile Systems Technology, Inc., a medical technology company, engages in the development and provision of medical devices for chronic diseases in the United States. The company offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema; and Entre system, a portable pneumatic compression device that is used for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers. The company was incorporated in 1995 and is headquartered in Minneapolis, Minnesota.
IPO Year: 2016
Exchange: NASDAQ
Website: tactilemedical.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
11/5/2024 | Outperform → Perform | Oppenheimer | |
11/5/2024 | Buy → Neutral | BTIG Research | |
9/26/2024 | $23.00 | Buy | B. Riley Securities |
10-Q - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Filer)
8-K - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Filer)
10-Q - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Filer)
8-K - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Filer)
8-K - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Filer)
SD - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Filer)
8-K - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Filer)
10-Q - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Filer)
8-K - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Filer)
DEFA14A - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Filer)
Oppenheimer downgraded Tactile Systems from Outperform to Perform
BTIG Research downgraded Tactile Systems from Buy to Neutral
B. Riley Securities initiated coverage of Tactile Systems with a rating of Buy and set a new price target of $23.00
BTIG Research reiterated coverage of Tactile Systems Technology with a rating of In-Line and set a new price target of $60.00 from $51.00 previously
MINNEAPOLIS, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that management will participate in the Piper Sandler 36th Annual Healthcare Conference, which is being held at the Lotte New York Palace in New York, NY from December 3rd – 5th. Management will participate in a fireside chat on Tuesday, December 3rd at 10:00 a.m. Central Time. A live audio webcast of the fireside chat will be accessible under the "Events & Webcasts" section of the Company's investor relations website at http://investors.tactilemedical.com. An ar
MINNEAPOLIS, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the third quarter ended September 30, 2024 and announced the adoption of a share repurchase program. Third Quarter 2024 Summary & Recent Business Highlights: Total revenue increased 5% year-over-year to $73.1 million Lymphedema product revenue increased 4% over Q3 2023Airway clearance product revenue increased 10% over Q3 2023 Net income of $5.2 million versus $22.3 million in Q3 2023Adjusted EBITDA of $10.7 million versus $7.7 million in Q3
MINNEAPOLIS, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that third quarter of fiscal year 2024 financial results will be released after the market closes on Monday, November 4, 2024. Management will host a conference call with a question and answer session at 5:00 p.m. Eastern Time on November 4, 2024, to discuss the results of the quarter. Those who would like to participate may dial 877-407-3088 (201-389-0927 for international callers) and provide access code 13748661. A live webcast of the call will also be provide
MINNEAPOLIS, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that Nimbl, its next-generation pneumatic compression platform, is now commercially available throughout the United States for the treatment of upper extremity lymphedema. Nimbl, which is significantly smaller and lighter than previous device iterations, is indicated as a treatment option for patients with both upper and lower extremity lymphedema, chronic edema, venous insufficiency, and wound healing. Nimbl received U.S Food & Drug Administration (FDA) 510(k) cl
MINNEAPOLIS, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced the publication of a new clinical study in the Journal of Vascular Surgery, Venous and Lymphatic Disorders. This study assessed outcomes associated with use of the Company's Flexitouch advanced pneumatic compression device (APCD) in Veterans with lower extremity lymphedema. Notably, this 52-week study represents the largest peer-reviewed, prospective, clinical trial investigating PCDs and lymphedema ever published in the United States. The prospective, longi
MINNEAPOLIS, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that the Pricing, Data Analysis, and Coding (PDAC) contractor for the Centers for Medicare & Medicaid Services (CMS) has approved the use of Healthcare Common Procedure Coding System (HCPCS) code E0651 for billing the Durable Medical Equipment Medicare Administrative Contractors for Nimbl™, the Company's next-generation pneumatic compression platform. PDAC approval is subsequent to the receipt of 510(k) clearance from the U.S. Food and Drug Administration (FDA) i
MINNEAPOLIS, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the second quarter ended June 30, 2024. Second Quarter 2024 Highlights: Total revenue increased 7% year-over-year to $73.2 million Lymphedema product revenue increased 8% year-over-yearAirway clearance product revenue increased 2% year-over-year Net income of $4.3 million versus a net loss of $0.1 million in Q2 2023Adjusted EBITDA of $9.1 million versus $6.1 million in Q2 2023Operating cashflow of $13.1 million, ended Q2 2024 with $73.6 mill
MINNEAPOLIS, July 22, 2024 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that second quarter of fiscal year 2024 financial results will be released after the market closes on Monday, August 5, 2024. Management will host a conference call with a question and answer session at 5:00 p.m. Eastern Time on August 5, 2024, to discuss the results of the quarter. Those who would like to participate may dial 877-407-3088 (201-389-0927 for international callers) and provide access code 13745955. A live webcast of the call will also be provided o
MINNEAPOLIS, May 21, 2024 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that management will participate in the William Blair 44th Annual Growth Stock Conference, which is being held at the Loews Hotel in Chicago, IL from June 4th - 6th. Management will participate in a fireside chat on Tuesday, June 4th at 9:20 a.m. Central Time. A live audio webcast of the fireside chat will be accessible under the "Events & Webcasts" section of the Company's investor relations website at http://investors.tactilemedical.com. An archive of the webcas
MINNEAPOLIS, May 06, 2024 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the first quarter ended March 31, 2024. First Quarter 2024 Summary: Total revenue increased 4% year-over-year to $61.1 million Lymphedema product revenue increased 5% year-over-yearAirway clearance product revenue decreased 4% year-over-year Net loss of $2.2 million versus $1.9 million in Q1 2023Adjusted EBITDA of $1.0 million versus $0.5 million in Q1 2023 Recent Business Highlights: Completed enrollment of 235 patients in a multi-center,
SC 13G/A - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Subject)
SC 13G - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Subject)
SC 13G - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Subject)
SC 13G/A - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Subject)
SC 13G - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Subject)
SC 13G/A - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Subject)
SC 13G - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Subject)
SC 13G - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Subject)
SC 13G - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Subject)
SC 13G/A - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Subject)
4 - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Issuer)
4 - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Issuer)
4 - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Issuer)
4 - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Issuer)
4 - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Issuer)
4 - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Issuer)
4 - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Issuer)
4 - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Issuer)
4 - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Issuer)
4 - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Issuer)
MINNEAPOLIS, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the third quarter ended September 30, 2024 and announced the adoption of a share repurchase program. Third Quarter 2024 Summary & Recent Business Highlights: Total revenue increased 5% year-over-year to $73.1 million Lymphedema product revenue increased 4% over Q3 2023Airway clearance product revenue increased 10% over Q3 2023 Net income of $5.2 million versus $22.3 million in Q3 2023Adjusted EBITDA of $10.7 million versus $7.7 million in Q3
MINNEAPOLIS, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that third quarter of fiscal year 2024 financial results will be released after the market closes on Monday, November 4, 2024. Management will host a conference call with a question and answer session at 5:00 p.m. Eastern Time on November 4, 2024, to discuss the results of the quarter. Those who would like to participate may dial 877-407-3088 (201-389-0927 for international callers) and provide access code 13748661. A live webcast of the call will also be provide
MINNEAPOLIS, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the second quarter ended June 30, 2024. Second Quarter 2024 Highlights: Total revenue increased 7% year-over-year to $73.2 million Lymphedema product revenue increased 8% year-over-yearAirway clearance product revenue increased 2% year-over-year Net income of $4.3 million versus a net loss of $0.1 million in Q2 2023Adjusted EBITDA of $9.1 million versus $6.1 million in Q2 2023Operating cashflow of $13.1 million, ended Q2 2024 with $73.6 mill
MINNEAPOLIS, July 22, 2024 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that second quarter of fiscal year 2024 financial results will be released after the market closes on Monday, August 5, 2024. Management will host a conference call with a question and answer session at 5:00 p.m. Eastern Time on August 5, 2024, to discuss the results of the quarter. Those who would like to participate may dial 877-407-3088 (201-389-0927 for international callers) and provide access code 13745955. A live webcast of the call will also be provided o
MINNEAPOLIS, May 06, 2024 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the first quarter ended March 31, 2024. First Quarter 2024 Summary: Total revenue increased 4% year-over-year to $61.1 million Lymphedema product revenue increased 5% year-over-yearAirway clearance product revenue decreased 4% year-over-year Net loss of $2.2 million versus $1.9 million in Q1 2023Adjusted EBITDA of $1.0 million versus $0.5 million in Q1 2023 Recent Business Highlights: Completed enrollment of 235 patients in a multi-center,
CEO Dan Reuvers to retire; Healthcare veteran and board director Sheri Dodd appointed as Chief Executive OfficerPreliminary, unaudited total revenue for first quarter of 2024 expected to be approximately $61 millionManagement to host conference call on May 6, 2024 to discuss first quarter 2024 financial results MINNEAPOLIS, April 23, 2024 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that Dan Reuvers will retire as the Company's Chief Executive Officer, effective June 30, 2024. Concurrently, the Company announced the appointment of
MINNEAPOLIS, April 15, 2024 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that first quarter of fiscal year 2024 financial results will be released after the market closes on Monday, May 6, 2024. Management will host a conference call with a question and answer session at 5:00 p.m. Eastern Time on May 6, 2024, to discuss the results of the quarter. Those who would like to participate may dial 877-407-3088 (201-389-0927 for international callers) and provide access code 13745955. A live webcast of the call will also be provided on the
MINNEAPOLIS, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter 2023 Highlights: Total revenue increased 5% over prior year to $77.7 millionNet income increased 77% over prior year to $8.2 millionAdjusted EBITDA increased 27% over prior year to $15.4 millionRetired $16.8 million revolving line of credit and completed final $5.6 million ea
MINNEAPOLIS, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that fourth quarter and fiscal year 2023 financial results will be released before the market opens on Tuesday, February 20th. Management will host a conference call with a question and answer session at 8:00 a.m. Eastern Time on February 20th to discuss the results of the quarter and fiscal year. Those who would like to participate may dial 877-407-3088 (201-389-0927 for international callers) and provide access code 13744163. A live webcast of the call will als
MINNEAPOLIS, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the third quarter ended September 30, 2023. Third Quarter 2023 Summary: Revenue increased 7% year-over-year to $69.6 million, compared to $65.3 million in third quarter 2022 Lymphedema revenue increased 15%Airway clearance revenue decreased 36% Operating income of $8.0 million, compared to operating loss of $1.6 million in third quarter 2022Net income of $22.3 million, compared to a net loss of $2.3 million in third quarter 2022Adjusted EBIT
PHILADELPHIA, Nov. 08, 2023 (GLOBE NEWSWIRE) -- LifeLens Technologies, Inc. (LifeLens), a medical technology company that provides real-time physiological monitoring, today announced the appointment of three industry veterans to the following positions on its executive leadership team and Board of Directors: Daniel J. Sullivan, Chairman of the Board of LifeLens, as Chief Executive OfficerBrent A. Moen as Chief Financial OfficerRichard J. Buchholz as a member of the Board of Directors "With LifeLens, we have a significant opportunity to disrupt healthcare and make a meaningful impact on patients and healthcare professionals, and we are thrilled to have Brent and Rick join the LifeLens tea
MINNEAPOLIS, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced the appointment of Vindell Washington, M.D. to the Company's Board of Directors ("Board"), effective October 2, 2023. "We are pleased to welcome Dr. Washington to Tactile Medical, who joins our Board with over 30 years of experience in the healthcare industry," said Bill Burke, Chairman of the Board of Tactile Medical. "We will benefit from his breadth of experience in medicine, technology and policy, as well as his expertise in advising healthcare companies on their clinical s
MINNEAPOLIS, July 18, 2023 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced the appointment of Sherri Ferstler to the position of Senior Vice President of Sales, effective July 31, 2023. Ms. Ferstler will succeed Eric Pauls, who will be resigning from the Company, effective July 28, 2023. "Sherri is a strategic leader with over 25 years of experience in the healthcare industry and a successful history of developing and leading high-performance teams at scale," said Dan Reuvers, President and Chief Executive Officer of Tactile Medical. "Sherri brings ex
MINNEAPOLIS, March 14, 2023 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced the appointment of Elaine Birkemeyer to the position of Chief Financial Officer, effective March 20, 2023. Ms. Birkemeyer will succeed Brent Moen, who is retiring. "Elaine is a dynamic and purpose-driven leader with over 25 years of experience in finance, accounting, and business strategy, including extensive senior leadership experience at multiple Fortune 500 companies, leading large divisions within the healthcare, consumer and retail industries," said Da
MINNEAPOLIS, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that Brent Moen has communicated his intention to retire as Chief Financial Officer in 2023. "I would like to thank Brent for his important contributions to our organization during his tenure," said Dan Reuvers, President and Chief Executive Officer of Tactile Medical. "Brent was instrumental in helping Tactile Medical to navigate the headwinds created by the COVID-19 pandemic, to successfully complete and integrate the acquisition of our AffloVest airway clearan
Avation Medical appoints Darren Wennen, a medical industry veteran, as Chief Marketing Officer in anticipation of commercialization of its wearable neuromodulation system to treat OAB and UUI. COLUMBUS, Ohio, April 13, 2022 /PRNewswire/ -- Avation Medical, an innovative neuromodulation and digital health company pioneering a wearable system to treat the symptoms of overactive bladder (OAB) and urge urinary incontinence (UUI), today announced the appointment of Darren Wennen as its Chief Marketing Officer. He will be responsible for all aspects of marketing, sales operations and customer care as the Company prepares to bring its novel wearable therapy and digital support system to market.
MINNEAPOLIS, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical") (NASDAQ:TCMD), a medical technology company focused on developing medical devices for the treatment of patients with underserved chronic diseases at home, today announced the appointment of Valerie L. Asbury and D. Brent Shafer to the Company's Board of Directors ("Board"), effective January 5, 2022. Ms. Asbury will serve as a member of both the Audit Committee and the Compliance & Reimbursement Committee. Mr. Shafer will serve as a member of the Audit Committee, the Compensation & Organization Committee, and the Nominating & Corporate Governance Committee. Three long-standing directors will
PONTE VEDRA, Fla., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgical treatment of Hallux Valgus (commonly known as bunions), today announced the appointment of Betsy Hanna and Deepti Jain to its Board of Directors effective October 1, 2021. "With decades of combined experience in healthcare leadership, Ms. Hanna and Ms. Jain strengthen the expertise of our Company's Board of Directors," said James T. Treace, the Company's Chairman of the Board. "Our executive leadership and board are pleased to add two individuals with their stellar reputa
MINNEAPOLIS, May 03, 2021 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical") (NASDAQ:TCMD), a medical technology company focused on developing medical devices for the at-home treatment of chronic diseases, today reported financial results for the first quarter ended March 31, 2021. First Quarter 2021 Summary: Total revenue decreased 2% year-over-year, to $42.8 million, compared to $43.7 million in first quarter 2020.Operating loss of $4.1 million, compared to operating loss of $4.5 million in first quarter 2020.Net loss of $2.3 million, compared to net loss of $1.3 million in first quarter 2020.Adjusted EBITDA loss of $7,000, compared to Adjusted EBITDA loss of $0.5
MINNEAPOLIS, April 20, 2021 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical") (NASDAQ:TCMD), a medical technology company focused on developing medical devices for the treatment of chronic diseases at home, today announced the appointment of Eric Pauls to the position of Senior Vice President of Sales, effective May 1, 2021. Mr. Pauls will succeed Bryan Rishe, who is retiring in May. "Eric is a strategic leader with over 20 years of experience in the healthcare industry and a proven history of building scale and leading high-performance teams," said Dan Reuvers, President and Chief Executive Officer of Tactile Medical. "His career has been dedicated to establishin
The Company continues to expect full year 2024 total revenue in the range of $300 million to $305 million, representing growth of approximately 9% to 11% year-over-year, compared to total revenue of $274.4 million in 2023.
Tactile Systems Tech (NASDAQ:TCMD) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.11) by 54.55 percent. This is a 66.67 percent decrease over losses of $(0.03) per share from the same period last year. The company reported quarterly sales of $61.088 million which beat the analyst consensus estimate of $59.175 million by 3.23 percent. This is a 3.81 percent increase over sales of $58.846 million the same period last year.
Tactile Systems Tech (NASDAQ:TCMD) reported quarterly earnings of $0.37 per share which beat the analyst consensus estimate of $0.22 by 68.18 percent. The company reported quarterly sales of $77.65 million which missed the analyst consensus estimate of $78.36 million by 0.91 percent. This is a 5.08 percent increase over sales of $73.90 million the same period last year.
Companies Reporting Before The Bell • Barclays (NYSE:BCS) is likely to report quarterly earnings at $0.36 per share on revenue of $7.38 billion. • Fresenius Medical Care (NYSE:FMS) is projected to report quarterly earnings at $0.32 per share on revenue of $5.35 billion. • NexPoint Residential (NYSE:NXRT) is projected to report earnings for its fourth quarter. • Summit Therapeutics (NASDAQ:SMMT) is likely to report earnings for its fourth quarter. • Axsome Therapeutics (NASDAQ:AXSM) is projected to report quarterly loss at $1.15 per share on revenue of $67.69 million. • Gran Tierra Energy (AMEX:GTE) is expected to report quarterly loss at $0.13 per share on revenue of $60 thousand. • O
Tactile Systems Tech (NASDAQ:TCMD) is set to give its latest quarterly earnings report on Tuesday, 2024-02-20. Here's what investors need to know before the announcement. Analysts estimate that Tactile Systems Tech will report an earnings per share (EPS) of $0.22. Tactile Systems Tech bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter. New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast). Past Earnings Performance Last quarter the company beat EPS by $0.81, which was followed by a 21.2
One of the hottest topics among members of Congress and investors has been the stock and options trading activity by several politicians. A new report reveals how several members of Congress outperformed the overall market, and also shares some of the top stocks and sectors picked the most by those in office. What Happened: Many stock indexes ended 2023 trading at all-time highs or near all-time highs, with 2023 turning into a rebound year for investors after a down 2022. A new report released by Unusual Whales highlighted the top traders in Congress with Brian Higgins (D-N.Y.) taking the crown with a 238.9% gain from 2023 trades. The report found that 32 members of Congress beat
Sen. Tina Smith’s (D-Minn.) significant November investment in a medical device maker’s stock has yielded a remarkable 48% return within just two months. What Happened: Smith purchased $250,000 worth of healthcare company Tactile Systems Technology (NASDAQ:TCMD) shares, a move labeled as “the most suspicious congressional stock trade in months” by Quiver Quantitative on social media. UPDATE$TCMD is now up 48% in the two months since Senator Smith made this trade.Ridiculous.Any politician who profits this much off a stock that they directly oversee should be required to put their money in a blind trust. pic.twitter.com/qeqGwjuV8A— Quiver Quantitative (@QuiverQuant) December 26, 2023